1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.

      Immunology today

      Sialoglycoproteins, immunology, Shock, Recombinant Proteins, Receptors, Interleukin-1, Receptors, Immunologic, Proteins, Leukemia, Myeloid, antagonists & inhibitors, Interleukin-1, Interleukin 1 Receptor Antagonist Protein, Humans, Disease Models, Animal, Arthritis, Animals

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Clinical and experimental evidence suggests that shock, arthritis, osteoporosis, colitis, leukemia, diabetes, wasting and atherosclerosis are mediated, in part, by interleukin 1 (IL-1). Inhibition of this cytokine has been a strategy for studying disease and for new drug development. A naturally-occurring IL-1 inhibitor (IL-1 receptor antagonist, IL-1ra) that blocks binding of IL-1 to its receptors has been cloned and produced in recombinant organisms. IL-1ra reduces the severity of sepsis, colitis, arthritis and diabetes in animals and is presently being tested in humans with arthritis, shock and myelogenous leukemia.

          Related collections

          Author and article information

          Journal
          10.1016/0167-5699(91)90142-G
          1838480

          Comments

          Comment on this article